PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

The impact of strong Programmed Death-ligand 1 (PD-L1) expression on the clinical outcomes of osimertinib in treatment naïve advanced Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) patients remains uncertain. We enrolled advanced NSCLC patients who harbored sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J. W., Huang, Yen-Hsiang, Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192769/
https://www.ncbi.nlm.nih.gov/pubmed/35697720
http://dx.doi.org/10.1038/s41598-022-13102-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192769/
https://www.ncbi.nlm.nih.gov/pubmed/35697720
http://dx.doi.org/10.1038/s41598-022-13102-7

Ejemplares similares